Balance Sheet Ascendis Pharma A/S

Stocks

ASND

DK0060615755

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			5-day change	1st Jan Change
218.06 ^USD	+1.14%		+3.62%	+2.26%

12/06	European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for Week	MT
12/06	Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years	MT

3fac22fd6e1e028c.rx3N5NzaBizAtSmH4HTh_rMkHaYGfe_faIqsNqp7csM.7XyirLiKUn-r9E_ulxvWsNpGK9BHFJnpDrPredIBAfvOdvuNhO40HvnQbA

Published financial data: ASCENDIS PHARMA A/S

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	77.78L	5.12Cr	27Cr	36Cr	72Cr
Total Revenues	77.78L	5.12Cr	27Cr	36Cr	72Cr
Cost of Goods Sold, Total	35.23L	1.21Cr	4.44Cr	4.43Cr	9.49Cr
Gross Profit	42.55L	3.9Cr	22Cr	32Cr	63Cr
Selling General & Admin Expenses, Total	16Cr	22Cr	26Cr	29Cr	46Cr
R&D Expenses	30Cr	38Cr	41Cr	31Cr	30Cr
Other Operating Expenses, Total	46Cr	60Cr	68Cr	60Cr	76Cr
Operating Income	-45Cr	-56Cr	-46Cr	-28Cr	-14Cr
Interest Expense, Total	-39.11L	-3.07Cr	-4.41Cr	-6.55Cr	-8.06Cr
Interest And Investment Income	7L	74.26L	1.69Cr	1.44Cr	1.53Cr
Net Interest Expenses	-32.19L	-2.33Cr	-2.72Cr	-5.11Cr	-6.53Cr
Income (Loss) On Equity Invest.	1.2Cr	-1.77Cr	-1.84Cr	-2.01Cr	1.63Cr
Currency Exchange Gains (Loss)	5.9Cr	4.48Cr	1.23Cr	-2.71Cr	7.82Cr
Other Non Operating Income (Expenses)	-	-1.98Cr	1.47Cr	38.74L	-11Cr
EBT, Excl. Unusual Items	-38Cr	-58Cr	-47Cr	-37Cr	-21Cr
EBT, Incl. Unusual Items	-38Cr	-58Cr	-47Cr	-37Cr	-21Cr
Income Tax Expense	-4L	53.77L	73.03L	48.43L	1.54Cr
Earnings From Continuing Operations	-38Cr	-58Cr	-48Cr	-38Cr	-23Cr
Net Income to Company	-38Cr	-58Cr	-48Cr	-38Cr	-23Cr
Net Income - (IS)	-38Cr	-58Cr	-48Cr	-38Cr	-23Cr
Net Income to Common Incl Extra Items	-38Cr	-58Cr	-48Cr	-38Cr	-23Cr
Net Income to Common Excl. Extra Items	-38Cr	-58Cr	-48Cr	-38Cr	-23Cr
Per Share Items
Net EPS - Basic	-7	-10.4	-8.55	-6.53	-3.76
Basic EPS - Continuing Operations	-7	-10.4	-8.55	-6.53	-3.76
Basic Weighted Average Shares Outstanding	5.48Cr	5.61Cr	5.63Cr	5.79Cr	6.06Cr
Net EPS - Diluted	-7	-10.4	-8.55	-6.53	-3.76
Diluted EPS - Continuing Operations	-7	-10.4	-8.55	-6.53	-3.76
Diluted Weighted Average Shares Outstanding	5.48Cr	5.61Cr	5.63Cr	5.79Cr	6.06Cr
Normalized Basic EPS	-4.38	-6.44	-5.26	-4.03	-2.19
Normalized Diluted EPS	-4.38	-6.44	-5.26	-4.03	-2.19
American Depositary Receipts Ratio (ADR)	0.07	0.07	0.07	0.07	0.07
Supplemental Items
EBITDA	-45Cr	-56Cr	-45Cr	-27Cr	-13Cr
EBITA	-45Cr	-56Cr	-46Cr	-28Cr	-14Cr
EBIT	-45Cr	-56Cr	-46Cr	-28Cr	-14Cr
EBITDAR	-45Cr	-56Cr	-45Cr	-27Cr	-
Effective Tax Rate - (Ratio)	0.1	-0.93	-1.54	-1.3	-7.23
Current Foreign Taxes	-4L	-	-	-	-
Total Current Taxes	-4L	53.77L	14.73L	34.15L	1.2Cr
Total Deferred Taxes	-	-	58.3L	14.28L	33.4L
Normalized Net Income	-24Cr	-36Cr	-30Cr	-23Cr	-13Cr
Interest on Long-Term Debt	33.96L	38.42L	35.81L	33.03L	41.86L
Supplemental Operating Expense Items
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	30Cr	38Cr	41Cr	31Cr	30Cr
Net Rental Expense, Total	2L	3L	4L	3L	-
Imputed Operating Lease Interest Expense	59.1T	2L	2L	2L	-
Imputed Operating Lease Depreciation	1L	55.89T	1L	85.99T	-
Stock-Based Comp., R&D Exp. (Total)	3.74Cr	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	2.94Cr	-	-	-	-
Stock-Based Comp., Other (Total)	30T	6.42Cr	6.67Cr	9.55Cr	12Cr
Total Stock-Based Compensation	6.68Cr	6.42Cr	6.67Cr	9.55Cr	12Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	45Cr	44Cr	39Cr	56Cr	62Cr
Short Term Investments	24Cr	29Cr	72.75L	-	-
Total Cash And Short Term Investments	68Cr	74Cr	40Cr	56Cr	62Cr
Accounts Receivable, Total	22L	1.19Cr	3.59Cr	17Cr	14Cr
Other Receivables	2.1Cr	1.37Cr	1.99Cr	1.12Cr	1.64Cr
Total Receivables	2.32Cr	2.56Cr	5.58Cr	18Cr	16Cr
Inventory	7.54Cr	13Cr	21Cr	30Cr	30Cr
Prepaid Expenses	2.52Cr	3.17Cr	3.86Cr	2.83Cr	3.37Cr
Total Current Assets	81Cr	92Cr	70Cr	106.09Cr	110.9Cr
Gross Property Plant And Equipment	16Cr	18Cr	18Cr	18Cr	22Cr
Accumulated Depreciation	-3.39Cr	-4.66Cr	-7.15Cr	-8.46Cr	-7.64Cr
Net Property Plant And Equipment	13Cr	13Cr	11Cr	9.87Cr	15Cr
Long-term Investments	15Cr	3.04Cr	56.86L	1.36Cr	3.25Cr
Goodwill	34.95L	34.95L	34.95L	34.95L	34.95L
Other Intangibles, Total	17.77L	13.33L	9L	5L	2L
Other Long-Term Assets, Total	18.08L	19.2L	21.27L	23.17L	1.09Cr
Total Assets	108.49Cr	108.97Cr	83Cr	117.95Cr	130.26Cr
Liabilities
Accounts Payable, Total	5.94Cr	10Cr	9.46Cr	9.64Cr	9.07Cr
Accrued Expenses, Total	3Cr	3.2Cr	4.12Cr	6.8Cr	-
Current Portion of Long-Term Debt	-	1.14Cr	1.12Cr	48Cr	47Cr
Current Portion of Leases	69.95L	1.4Cr	1.42Cr	1.55Cr	2.04Cr
Current Income Taxes Payable	2L	54.9L	22.99L	12.22L	64.27L
Unearned Revenue Current, Total	26.01L	-	11.84L	9L	49.44L
Other Current Liabilities	11.93L	73.39L	3.27Cr	25Cr	48Cr
Total Current Liabilities	10Cr	17Cr	20Cr	91Cr	106.94Cr
Long-Term Debt	-	39Cr	53Cr	29Cr	25Cr
Long-Term Leases	9.8Cr	9.52Cr	8.46Cr	7.75Cr	13Cr
Unearned Revenue Non Current	29.64L	1.42Cr	59.49L	50L	11.23L
Deferred Tax Liability Non Current	-	-	58.3L	72.58L	96.23L
Other Non Current Liabilities	-	16Cr	14Cr	-	-
Total Liabilities	20Cr	83Cr	97Cr	128.52Cr	146.54Cr
Common Stock, Total	76.46L	76.75L	77.49L	81.49L	83.22L
Additional Paid In Capital	210.77Cr	211.29Cr	212.31Cr	244.42Cr	253.11Cr
Retained Earnings	-141.39Cr	-186.05Cr	-227.71Cr	-255.97Cr	-270.04Cr
Treasury Stock	-2.16Cr	-1L	-1L	-1L	-80T
Comprehensive Income and Other	20Cr	34.52L	7L	17.83L	-17.55L
Total Common Equity	88Cr	26Cr	-15Cr	-11Cr	-16Cr
Total Equity	88Cr	26Cr	-15Cr	-11Cr	-16Cr
Total Liabilities And Equity	108.49Cr	108.97Cr	83Cr	117.95Cr	130.26Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	5.68Cr	5.6Cr	5.66Cr	5.98Cr	6.14Cr
ECS Total Common Shares Outstanding	5.68Cr	5.6Cr	5.66Cr	5.98Cr	6.14Cr
Book Value / Share	15.56	4.7	-2.57	-1.77	-2.65
Tangible Book Value	88Cr	26Cr	-15Cr	-11Cr	-17Cr
Tangible Book Value Per Share	15.47	4.61	-2.65	-1.83	-2.71
Total Debt	10Cr	51Cr	64Cr	86Cr	87Cr
Net Debt	-68Cr	-23Cr	24Cr	30Cr	26Cr
Debt Equivalent Oper. Leases	14.88L	22.4L	28.24L	22.8L	-
Equity Method Investments, Total	3.83Cr	2.29Cr	56.86L	1.36Cr	3.25Cr
Account Code - Inventory Valuation	3	3	3	3	3
Inventories - Raw Materials, Total	22.48L	96.16L	1.86Cr	1.76Cr	1.91Cr
Inventories - Work In Process, Total	6.89Cr	11Cr	17Cr	24Cr	25Cr
Inventories - Finished Goods, Total	42.92L	81.72L	1.93Cr	4.23Cr	2.9Cr
Machinery, Total	2.58Cr	3.61Cr	3.89Cr	3.29Cr	3.76Cr
Full Time Employees	639	797	879	1.02T	1.19T

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-38Cr	-58Cr	-48Cr	-38Cr	-23Cr
Depreciation & Amortization - CF	1.49Cr	1.75Cr	1.84Cr	1.72Cr	1.72Cr
Depreciation & Amortization, Total	1.49Cr	1.75Cr	1.84Cr	1.72Cr	1.72Cr
Amortization of Deferred Charges, Total - (CF)	4L	4L	5L	5L	5L
(Gain) Loss From Sale Of Asset	-	22T	5T	-91T	-
Asset Writedown & Restructuring Costs	-	-	78.34L	-	52.83L
(Income) Loss On Equity Investments - (CF)	-1.2Cr	1.77Cr	1.84Cr	2.01Cr	-1.63Cr
Stock-Based Compensation (CF)	6.68Cr	6.42Cr	6.67Cr	9.55Cr	12Cr
Other Operating Activities, Total	-5.53Cr	62.55L	20.67L	4.58Cr	8.81Cr
Change In Accounts Receivable	-66.59L	-1.15Cr	-3.28Cr	-12Cr	1.56Cr
Change In Inventories	-7.54Cr	-5.53Cr	-7.83Cr	-8.67Cr	-59.2L
Change In Accounts Payable	3.92Cr	4.59Cr	35.51L	2.7Cr	-1.04Cr
Change in Unearned Revenues	52.02L	86.48L	-70.8L	-11.97L	1L
Change in Other Net Operating Assets	-1.12Cr	-64.09L	1.48Cr	7.24Cr	7.15Cr
Cash from Operations	-42Cr	-50Cr	-47Cr	-31Cr	5.39Cr
Capital Expenditure	-2.37Cr	-1.45Cr	-24.42L	-14.27L	-84.85L
Sale of Property, Plant, and Equipment	-	-	51T	10L	-
Sale (Purchase) of Intangible assets	-5L	-	-	-	-
Investment in Marketable and Equity Securities, Total	-8.63Cr	6.67Cr	29Cr	73.53L	-
Other Investing Activities, Total	-	95.35L	-	-	-
Cash from Investing	-11Cr	6.17Cr	29Cr	68.76L	-84.85L
Long-Term Debt Issued, Total	-	50Cr	14Cr	13Cr	-
Total Debt Issued	-	50Cr	14Cr	13Cr	-
Long-Term Debt Repaid, Total	-64.29L	-63.56L	-1.04Cr	-1.14Cr	-2.2Cr
Total Debt Repaid	-64.29L	-63.56L	-1.04Cr	-1.14Cr	-2.2Cr
Issuance of Common Stock	38Cr	51.53L	1.03Cr	34Cr	8.71Cr
Repurchase of Common Stock	-2.16Cr	-11Cr	-18.12L	-	-2.88Cr
Other Financing Activities, Total	-	-	-	-1.93Cr	-
Cash from Financing	35Cr	40Cr	13Cr	44Cr	3.63Cr
Foreign Exchange Rate Adjustments	3.86Cr	3.57Cr	-60.08L	2.28Cr	-2.52Cr
Net Change in Cash	-14Cr	-15L	-5.26Cr	17Cr	5.65Cr
Supplemental Items
Cash Interest Paid	18.41L	92.94L	1.57Cr	1.52Cr	2.29Cr
Cash Income Tax Paid (Refund)	-2L	3T	44.66L	55.12L	66.79L
Levered Free Cash Flow	-28Cr	-31Cr	-32Cr	-20Cr	16Cr
Unlevered Free Cash Flow	-28Cr	-30Cr	-29Cr	-16Cr	22Cr
Change In Net Working Capital	5.51Cr	1.17Cr	8.92Cr	9.69Cr	-17Cr
Net Debt Issued / Repaid	-64.29L	50Cr	13Cr	12Cr	-2.2Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-27.35	-32.29	-29.73	-17.38	-6.86
Return on Total Capital	-29.42	-39.89	-44.83	-27.89	-11.67
Return On Equity %	-44.54	-101.69	-818.43	300.78	169.84
Return on Common Equity	-44.54	-101.69	-818.43	300.78	169.84
Margin Analysis
Gross Profit Margin %	54.71	76.28	83.36	87.83	86.82
SG&A Margin	2.06T	432.3	99.13	80.06	63.58
EBITDA Margin %	-5.76T	-1.09T	-168.34	-75.3	-18.25
EBITA Margin %	-5.81T	-1.1T	-170.79	-76.66	-18.92
EBIT Margin %	-5.81T	-1.1T	-170.79	-76.66	-18.92
Income From Continuing Operations Margin %	-4.93T	-1.14T	-180.51	-103.97	-31.67
Net Income Margin %	-4.93T	-1.14T	-180.51	-103.97	-31.67
Net Avail. For Common Margin %	-4.93T	-1.14T	-180.51	-103.97	-31.67
Normalized Net Income Margin	-3.09T	-705.7	-111.11	-64.15	-18.46
Levered Free Cash Flow Margin	-3.62T	-614.31	-119.34	-55.09	22.87
Unlevered Free Cash Flow Margin	-3.59T	-576.84	-109.01	-43.83	29.87
Asset Turnover
Asset Turnover	0.01	0.05	0.28	0.36	0.58
Fixed Assets Turnover	0.07	0.4	2.23	3.47	5.87
Receivables Turnover (Average Receivables)	6.01	7.25	11.16	3.6	4.68
Inventory Turnover (Average Inventory)	-	0.12	0.26	0.18	0.32
Short Term Liquidity
Current Ratio	8.03	5.39	3.56	1.17	1.04
Quick Ratio	7.03	4.44	2.31	0.81	0.72
Operating Cash Flow to Current Liabilities	-4.16	-2.89	-2.37	-0.34	0.05
Days Sales Outstanding (Average Receivables)	60.7	50.32	32.7	101.73	77.96
Days Outstanding Inventory (Average Inventory)	-	3.1T	1.4T	2.09T	1.15T
Average Days Payable Outstanding	-	434.42	291.04	266.89	338.53
Cash Conversion Cycle (Average Days)	-	2.71T	1.14T	1.92T	887.6
Long Term Solvency
Total Debt/Equity	11.88	193.04	-442.2	-810.38	-535.43
Total Debt / Total Capital	10.62	65.88	129.22	114.08	122.97
LT Debt/Equity	11.09	183.39	-424.76	-345.37	-236.61
Long-Term Debt / Total Capital	9.91	62.58	124.13	48.62	54.34
Total Liabilities / Total Assets	18.55	75.83	117.65	108.96	112.5
EBIT / Interest Expense	-115.52	-18.31	-10.34	-4.26	-1.69
EBITDA / Interest Expense	-111.7	-17.74	-9.92	-3.99	-1.48
(EBITDA - Capex) / Interest Expense	-117.76	-18.21	-9.98	-4.01	-1.58
Total Debt / EBITDA	-0.24	-0.93	-1.47	-3.28	-7.32
Net Debt / EBITDA	1.57	0.43	-0.56	-1.14	-2.15
Total Debt / (EBITDA - Capex)	-0.23	-0.91	-1.47	-3.26	-6.83
Net Debt / (EBITDA - Capex)	1.49	0.42	-0.56	-1.13	-2.01
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	11.87	557.93	421.2	36.34	98.03
Gross Profit, 1 Yr. Growth %	-38.8	817.44	469.52	43.66	95.76
EBITDA, 1 Yr. Growth %	36.52	24.17	-19.25	-39.01	-52.01
EBITA, 1 Yr. Growth %	36.65	24.35	-18.92	-38.81	-51.12
EBIT, 1 Yr. Growth %	36.65	24.35	-18.92	-38.81	-51.12
Earnings From Cont. Operations, 1 Yr. Growth %	-8.44	52.04	-17.45	-21.47	-39.69
Net Income, 1 Yr. Growth %	-8.44	52.04	-17.45	-21.47	-39.69
Normalized Net Income, 1 Yr. Growth %	-8.4	50.5	-17.94	-21.28	-43.03
Diluted EPS Before Extra, 1 Yr. Growth %	-15.39	48.52	-17.76	-23.65	-42.39
Accounts Receivable, 1 Yr. Growth %	468.48	441.36	201.21	363.51	-15
Inventory, 1 Yr. Growth %	-	73.29	59.89	41.49	2
Net Property, Plant and Equip., 1 Yr. Growth %	16.59	2.42	-14.3	-10.77	48.39
Total Assets, 1 Yr. Growth %	10.73	0.44	-24.24	42.87	10.43
Tangible Book Value, 1 Yr. Growth %	5.45	-70.57	-158.07	-26.9	51.76
Common Equity, 1 Yr. Growth %	5.36	-70.2	-155.32	-27.45	54.03
Cash From Operations, 1 Yr. Growth %	53.8	18.69	-5.72	-34.48	-117.6
Capital Expenditures, 1 Yr. Growth %	19.36	-38.88	-83.15	-41.56	494.6
Levered Free Cash Flow, 1 Yr. Growth %	64.69	11.52	1.25	-39.84	-182.23
Unlevered Free Cash Flow, 1 Yr. Growth %	64.42	5.63	-1.5	-47.82	-234.97
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-23.74	171.29	485.59	166.57	64.32
Gross Profit, 2 Yr. CAGR %	-43.6	136.95	622.84	186.03	67.7
EBITDA, 2 Yr. CAGR %	40.99	31.58	1.38	-29.07	-45.17
EBITA, 2 Yr. CAGR %	41.16	30.36	0.41	-29.56	-45.31
EBIT, 2 Yr. CAGR %	41.16	30.36	0.41	-29.56	-45.31
Earnings From Cont. Operations, 2 Yr. CAGR %	32.64	17.98	12.03	-19.48	-31.18
Net Income, 2 Yr. CAGR %	32.64	17.98	12.03	-19.48	-31.18
Normalized Net Income, 2 Yr. CAGR %	32.63	17.41	11.13	-19.63	-33.03
Diluted EPS Before Extra, 2 Yr. CAGR %	22.23	12.1	10.52	-20.76	-33.68
Accounts Receivable, 2 Yr. CAGR %	65.42	454.75	303.81	273.65	98.49
Inventory, 2 Yr. CAGR %	-	-	66.46	50.41	20.13
Net Property, Plant and Equip., 2 Yr. CAGR %	67.24	9.27	-6.31	-12.56	15.06
Total Assets, 2 Yr. CAGR %	26.62	5.46	-12.77	4.04	25.61
Tangible Book Value, 2 Yr. CAGR %	21.64	-44.29	-58.66	-34.85	5.33
Common Equity, 2 Yr. CAGR %	21.65	-43.97	-59.39	-36.64	5.71
Cash From Operations, 2 Yr. CAGR %	54.07	35.11	5.78	-21.41	-66.04
Capital Expenditures, 2 Yr. CAGR %	114.35	-14.59	-67.9	-68.62	86.4
Levered Free Cash Flow, 2 Yr. CAGR %	69.36	35.51	6.26	13.17	-29.66
Unlevered Free Cash Flow, 2 Yr. CAGR %	69.29	31.78	2	7.76	-16.07
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-9.75	56.41	237.26	260.25	141.43
Gross Profit, 3 Yr. CAGR %	-26.19	42.91	217.4	321.83	152.07
EBITDA, 3 Yr. CAGR %	42.77	35.15	11.81	-14.42	-37.73
EBITA, 3 Yr. CAGR %	42.92	35.32	11.28	-14.87	-37.64
EBIT, 3 Yr. CAGR %	42.92	35.32	11.28	-14.87	-37.64
Earnings From Cont. Operations, 3 Yr. CAGR %	43.39	38.82	4.74	-0.48	-26.88
Net Income, 3 Yr. CAGR %	43.39	38.82	4.74	-0.48	-26.88
Normalized Net Income, 3 Yr. CAGR %	43.29	38.34	4.19	-0.94	-28.34
Diluted EPS Before Extra, 3 Yr. CAGR %	30.29	30.43	1.1	-2.3	-28.75
Accounts Receivable, 3 Yr. CAGR %	615.74	145.59	352.57	322.8	128.09
Inventory, 3 Yr. CAGR %	-	-	-	57.68	32.14
Net Property, Plant and Equip., 3 Yr. CAGR %	207.74	42.02	0.77	-7.82	4.3
Total Assets, 3 Yr. CAGR %	50.39	17.21	-5.55	2.83	6.13
Tangible Book Value, 3 Yr. CAGR %	46.99	-24.2	-43.52	-50.01	-13.64
Common Equity, 3 Yr. CAGR %	46.67	-23.88	-44.2	-50.73	-14.81
Cash From Operations, 3 Yr. CAGR %	44.37	41.24	19.84	-9.83	-52.27
Capital Expenditures, 3 Yr. CAGR %	107.64	41.09	-50.27	-60.81	-16.34
Levered Free Cash Flow, 3 Yr. CAGR %	59.45	47.34	22.97	-10.76	1.74
Unlevered Free Cash Flow, 3 Yr. CAGR %	59.05	44.66	19.59	-17.07	16.16
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	11.05	101.78	90.68	93.59	152.96
Gross Profit, 5 Yr. CAGR %	-1.57	91.14	83.86	88.63	145.91
EBITDA, 5 Yr. CAGR %	44.03	38.07	23.88	3.98	-16.37
EBITA, 5 Yr. CAGR %	44.02	38.18	24.1	4.22	-16.24
EBIT, 5 Yr. CAGR %	44.02	38.18	24.1	4.22	-16.24
Earnings From Cont. Operations, 5 Yr. CAGR %	41.13	36.32	29.91	11.64	-11.45
Net Income, 5 Yr. CAGR %	41.13	36.32	29.91	11.64	-11.45
Normalized Net Income, 5 Yr. CAGR %	41.07	35.96	29.44	11.33	-12.69
Diluted EPS Before Extra, 5 Yr. CAGR %	22.12	23.07	21.99	6.86	-14.59
Accounts Receivable, 5 Yr. CAGR %	50.28	129.27	469.28	190.48	225.47
Net Property, Plant and Equip., 5 Yr. CAGR %	121.77	119.1	91.24	16.98	6.26
Total Assets, 5 Yr. CAGR %	41.68	38.87	20.95	11.75	5.86
Tangible Book Value, 5 Yr. CAGR %	38.38	7.07	-11.5	-28.65	-27.53
Common Equity, 5 Yr. CAGR %	37.99	7.06	-12.25	-29.27	-27.95
Cash From Operations, 5 Yr. CAGR %	47.32	39.13	27.48	11.72	-27.63
Capital Expenditures, 5 Yr. CAGR %	103.93	72.78	-1.61	-22.67	-15.64
Levered Free Cash Flow, 5 Yr. CAGR %	52.78	41.4	35.56	15.31	-0.77
Unlevered Free Cash Flow, 5 Yr. CAGR %	52.52	39.66	33.16	10.32	4.82